<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358383</url>
  </required_header>
  <id_info>
    <org_study_id>D1120C00040</org_study_id>
    <nct_id>NCT01358383</nct_id>
  </id_info>
  <brief_title>Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral
      Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed maximum concentration (Cmax)</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time of maximum concentration (tmax)</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the concentration-time curve from zero to time of last quantifiable concentration (AUC(0-t))</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the concentration-time curve from zero to infinity (AUC)</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent terminal rate constant (Î»z), apparent terminal half-life (t1/2)</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent systemic clearance after extravascular dosing (CL/F)</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>apparent volume of distribution following extravascular dosing (Vz/F) for naproxen and esomeprazole</measure>
    <time_frame>Pharmacokinetic samples will be collected at pre-dose, 10, 20, 30, and 45 minutes post-dose, and 1, 1.5, 2,2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. The 72 hour post-dose sample will be collected at Visit 3 (Follow-up).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of Adverse events during the study as a measure of safety and tolerability</measure>
    <time_frame>Collected from administration of VIMOVO (Visit 2 [Residential period] Day 1) until the end of the study, including follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalties in Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) as a measure of safety and tolerability</measure>
    <time_frame>Labs will be taken from screening to follow up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities in Vital signs as a measure of safety and tolerability</measure>
    <time_frame>From screening to follow up visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>250mg, oral dose</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>20mg, oral dose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects aged 18 to 55 years

          -  Capable of understanding and complying with the Clinical Study Protocol

          -  Body mass index (BMI) of 19 to 30 kg/m2 and weight of 50 to 100 kg

        Exclusion Criteria:

          -  Previous enrollment in the present study

          -  Receipt of another investigational product within 4 weeks before this study or plans
             to participate in another study at the same time as this study

          -  Female subjects with a positive urine pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sostek</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Fransson</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelly Craven</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase I Services, Overland Park, Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Juvenile Idiopathic Arthritis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>VIMOVO</keyword>
  <keyword>fasting state</keyword>
  <keyword>Amount of VIMOVO in the blood</keyword>
  <keyword>taken on empty stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

